Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Hemophilia of Georgia tells lawmakers telehealth, 340B pharmacy and gene therapy are key to keeping patients in care
Summary
Hemophilia of Georgia told a House committee that roughly 2,000 diagnosed patients in the state rely on a nonprofit 340B pharmacy and outreach programs to cover treatment costs — which the group estimates at $300,000–$500,000 per patient in a ‘good year’ — and urged permanent telehealth flexibilities and protections for the 340B program.
Michelle Condie, senior director of advocacy for Hemophilia of Georgia, told a House Health Committee the nonprofit supports about 2,000 diagnosed patients in Georgia and urged lawmakers to protect telehealth flexibilities and the 340B program that subsidizes treatment.
Condie said roughly 33,000 people nationally have hemophilia and that HOG’s nonprofit pharmacy, administered under the 340B program, helps reduce treatment costs for its patients. “Our patients' cost of treatment and care annually, it's between 300 and 500,000, and that's for a good year,” Condie said, adding that severe cases can exceed $1,000,000 and that HOG has seen hospital bills reach millions of dollars.
The presentation explained that…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
